Viatris Inc. (VTRS) — ESG & Values Scores

Environment story

Viatris reports commitments to environmental stewardship including renewable energy adoption, energy efficiency projects, and supply-chain sustainability via AMR Alliance membership. However, the company discloses no quantified Scope 1, 2, or 3 emissions baselines, no net-zero target year, and no third-party verified decarbonization roadmap in accessible filings. The 10-K sustainability reference points to a 2024 Sustainability Report (published May 2025) not incorporated by reference, limiting audit transparency. No evidence of carbon-offset dependency detected, but absence of operational emission metrics and a disclosed net-zero deadline triggers material deductions. The company faces manufacturing facility compliance challenges (FDA warning letter at Indore facility 2024; fire at Nashik facility Feb 2026), raising operational-risk concerns but not directly tied to environmental violations.

Criticisms on file

FDA Warning Letter and Import Alert – Indore, India facility (2024). FDA inspection identified GMP deficiencies. Import alert affects 11 products; facility banned from U.S. market pending remediation and reinspection (anticipated 2026).
Source: VTRS 10-K 2025, Item 1 (Operations section)
Fire at Nashik, India oral solid dose manufacturing facility (February 2026). Manufacturing temporarily suspended; company expects resumption in April 2026. Insurance coverage status uncertain.
Source: VTRS 10-K 2025, Item 1 (Operations section)

Disclosed initiatives

Renewable Energy and Energy Efficiency

Company reports increasing renewable energy usage, implementing energy-efficiency projects, preventing refrigerant leaks, transitioning to greener refrigerants, using alternative fuels and technologies, and leveraging infrastructure upgrades.

Directional progress stated but no quantified baseline or targets disclosed.
AMR Industry Alliance Compliance

Viatris committed to the Antibiotic Manufacturing Standard across internal and external supply chain.

Supports responsible manufacturing practices but does not directly address carbon or climate.
Pharmaceutical Supply Chains Initiative

Company leveraging membership for external supplier sustainability engagement.

External supply-chain oversight mechanism in place but scope and effectiveness unclear.

Social story

Viatris discloses 30,000+ employees globally and reports recent accolades including Forbes World's Best Employers, TIME World's Most Sustainable Companies, and TIME World's Top Companies for Women. The company describes workforce engagement initiatives (Elevate program for health/wellness, employee-led ambassador network) and workplace culture focus. However, the 10-K and proxy contain no disclosed CEO-to-median-worker pay ratio, no union representation or labor-relations standing data, no leadership diversity percentages by gender or race, and no supply-chain human-rights audit results or risk disclosures. One major facility (Indore, India) faced FDA inspection findings requiring remediation, suggesting quality-control lapses but not directly a labor/human-rights violation. Absence of quantified diversity metrics, union-activity disclosure, and supply-chain audits limits assessment robustness. Company does not disclose evidence of union suppression or active strikes in the past 24 months.

Criticisms on file

No documented union-suppression activities or major strikes disclosed in past 24 months. However, company discloses no union representation or labor-relations standing data.
Source: VTRS 10-K 2025 and Proxy 2026 – no labor relations or union disclosure provided.

Disclosed initiatives

Elevate Program

Global health, purpose, and growth initiative for all employees including mental health support via employee assistance programs and partnership with Unmind.

Provides universal wellness tools and resources; focus on mental health and employee wellbeing.
Executive and Management Development

Expanded professional development opportunities aligned with company strategy and career progression.

Supports talent development and internal succession planning.
Inclusion and Workplace Culture

Company emphasizes listening, inclusion, mutual respect, and colleague connection. Annual pulse surveys measure employee engagement and sense of inclusion.

Cultural alignment with mission; employee engagement monitoring in place.
Global Environmental, Health and Safety Management System

Comprehensive EHS program with technical requirements, processes, and systems for health/safety across all locations.

Establishes foundation for occupational health and safety culture.

Governance story

Viatris reports a single-class common-stock structure (one share, one vote), an independent Board Chair (elected 2023), and 12 of 13 Directors classified as independent under NASDAQ rules. Board composition reflects recent refreshment (7 new Directors since Dec 2022) with focus on C-suite, pharmaceutical, scientific, regulatory, accounting, and financial expertise. Board committees cover audit, compensation, compliance/risk, executive, finance, governance/sustainability, and science/technology. No evidence of dual-class share structure or unequal voting rights. Company discloses no specific annual lobbying expenditure figures or targeted climate-deregulation/consumer-protection lobbying, limiting assessment of regulatory-capture risk. No active shareholder climate litigation or antitrust proceedings disclosed; FDA facility compliance issues (warning letter, fire) are operational rather than governance failures per se. Governance structure supports oversight but lacks transparency on political spending.

Criticisms on file

No disclosure of annual lobbying expenditures or specific legislative positions on climate regulation or consumer protection. Governance transparency in political spending is limited.
Source: VTRS 10-K 2025 and Proxy 2026 – no lobbying spend or regulatory position disclosures provided.

Disclosed initiatives

Independent Board Chair

Board Chair is independent; elected 2023. Supports separation of Chair and CEO roles.

Enhances Board independence and oversight of management.
Declassified Board and Annual Elections

All Directors stand for election annually; no staggered board.

Strengthens shareholder accountability and director responsiveness.
Majority Voting Standard

Uncontested director elections use majority-vote threshold with director resignation provision.

Ensures elected directors have majority shareholder support.
Proxy Access

Shareholders meeting 3-year holding and other requirements may nominate and include director candidates in proxy materials.

Enables shareholder participation in Board composition.
Comprehensive Board Committee Structure

Audit, Compensation, Compliance and Risk Oversight, Executive, Finance, Governance and Sustainability, and Science and Technology committees with defined oversight responsibilities.

Distributes governance and risk oversight across specialized committees.
Strategic Review Committee

Non-standing committee formed April 2025 to support enterprise-wide strategic review and Board alignment on cost-saving and restructuring initiatives.

Provides focused governance for major corporate transformations.
Board Diversity and Inclusion Policy

Formalizes commitment to fostering diverse Board composition in areas including gender, race, ethnicity, age, and professional experience, subject to applicable law.

Articulates commitment to diverse perspectives in Board decision-making.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Viatris Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Viatris Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)